Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Sheila A. Denton, Executive Vice President and General Counsel at Incyte CORP (NASDAQ:INCY), a $15.2 billion market cap biopharmaceutical company with a "GREAT" financial health rating according to InvestingPro, sold 598 shares of common stock on August 4, 2025, at a price of $75.77, totaling $45,310. On the same day, Denton exercised options to acquire 598 shares of Incyte common stock at $58.06, for a total value of $34,719.
The sale transaction decreased Denton’s direct ownership to 33,200 shares, which includes 32,544 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested. The stock is currently trading near its 52-week high of $83.95, having delivered a 27% return over the past year.
The exercised options were part of an employee stock option plan, which became exercisable beginning October 2, 2023, in 37 installments, with the first 25% vesting on October 2, 2024, and the remainder vesting monthly over three years. Following the option exercise, Denton directly owns 15,560 options. For deeper insights into Incyte’s valuation and 10 additional key investment tips, visit InvestingPro.
In other recent news, Incyte announced that its Executive Vice President and Chief Financial Officer, Christiana Stamoulis, will step down in September 2025 to pursue another opportunity. The company is actively searching for her successor to ensure a smooth transition. Barclays (LON:BARC) initiated coverage on Incyte with an Overweight rating and a $90 price target, citing the company’s potential for revenue growth with maturing assets. RBC Capital raised its price target for Incyte to $72, maintaining a Sector Perform rating, due to strong demand for products like Jakafi and Niktimvo, and better-than-expected Opzelura performance. BMO Capital also adjusted its price target to $60 from $52, maintaining an Underperform rating, while expressing some optimism following the second-quarter earnings results under the new CEO. Truist Securities increased its price target to $79, maintaining a Hold rating, after Incyte’s second-quarter earnings exceeded expectations, with Jakafi sales reaching $764 million, surpassing the consensus estimate of $743 million. These developments reflect recent strategic and financial shifts within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.